Physician profile
Ari H Elman
NPI 1780997593
$5,192.33
in general payments reported to CMS, 2019-2025
43 companies · $4,090 in 2025
The $4,090 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2021: $51.65 · 2023: $484 · 2024: $243 · 2025: $4,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,700 · Long Term Medical Supply Or Device Loan: $897 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,700.06 |
| Long Term Medical Supply Or Device Loan | $897.30 |
| Education | $219.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,197.59 | 2023-2025 | |
| Janssen Biotech, INC. | $686.20 | 2025 | Tecvayli, Darzalex, Rybrevant |
| Astellas Pharma US INC | $306.35 | 2019-2025 | Padcev, Xtandi |
| Pfizer INC. | $221.29 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $203.58 | 2023-2025 | Calquence, Imfinzi, Enhertu |
| Merck Sharp & Dohme LLC | $196.76 | 2019-2025 | Keytruda, Keytruda Qlex, Welireg |
| E.R. Squibb & Sons, L.L.C. | $189.49 | 2023-2025 | Opdivo, Krazati, Opdualag |
| Abbvie INC. | $184.81 | 2023-2025 | |
| Gilead Sciences, INC. | $148.85 | 2023-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $126.54 | 2025 | |
| Genzyme Corporation | $123.84 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $123.48 | 2023-2025 | Ultomiris |
| Foundation Medicine, INC. | $114.00 | 2019 | |
| Celgene Corporation | $106.68 | 2025 | Reblozyl |
| Array Biopharma INC | $98.10 | 2025 | Braftovi, Mektovi, Lorbrena |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $80.30 | 2021-2025 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $76.25 | 2025 | Libtayo |
| Lilly USA, LLC | $69.65 | 2023 | Retevmo, Jaypirca, Verzenio |
| Glaxosmithkline, LLC. | $65.10 | 2025 | Zejula, Jemperli, Blenrep |
| Pharmaessentia USA Corporation | $64.56 | 2025 | Besremi |
| Beigene USA, INC. | $60.91 | 2024-2025 | Brukinsa |
| Beone Medicines USA, INC. | $56.02 | 2025 | Brukinsa, Tevimbra |
| Genentech USA, INC. | $55.92 | 2025 | Venclexta, Polivy |
| Ipsen Biopharmaceuticals, INC | $53.98 | 2025 | Onivyde |
| Tersera Therapeutics LLC | $53.78 | 2025 | Zoladex |
| Puma Biotechnology, INC. | $51.70 | 2025 | |
| Exelixis INC. | $45.33 | 2025 | Cabometyx |
| Tempus Ai, INC | $44.69 | 2024 | Xt Cdx |
| Iovance Biotherapeutics, INC. | $39.84 | 2025 | Amtagvi |
| Aveo Pharmaceuticals, INC. | $36.47 | 2025 | |
| Myriad Genetic Laboratories, INC. | $31.38 | 2021-2025 | Myrisk |
| Syndax Pharmaceuticals, INC. | $29.81 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.58 | 2025 | Vpriv |
| Corcept Therapeutics | $26.88 | 2025 | Korlym |
| Caris Mpi, INC. | $26.25 | 2025 | Mi Cancer Seek |
| Spectrum Pharmaceuticals INC. | $25.26 | 2025 | Rolvedon |
| Morphosys, US INC. | $24.79 | 2023 | Monjuvi |
| Springworks Therapeutics, INC. | $24.03 | 2025 | Ogsiveo |
| Rigel Pharmaceuticals, INC. | $22.80 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Immunocore Limited | $21.91 | 2025 | Kimmtrak |
| Eisai INC. | $19.79 | 2025 | |
| Incyte Corporation | $14.50 | 2025 | Jakafi, Niktimvo |
| Seagen INC. | $13.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ari Elman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.